New pill targets Hard-to-Treat cancers in early human trial

NCT ID NCT07542704

Not yet recruiting Disease control Sponsor: Kumquat Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests an experimental oral drug called KQB368 in 48 adults with advanced solid tumors (like lung, colorectal, or uterine cancer) that have a specific KRAS mutation (G12C or G12S). The main goals are to find a safe dose and see if the drug can shrink tumors. Participants take the drug daily in 21-day cycles and visit the clinic regularly for monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KQB368 (oral drug)
What this could lead to: If it works, this could point toward a new treatment option for people with certain KRAS-mutated cancers that have stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 48 participants, so it is primarily testing safety and dosing. It is too soon to know if KQB368 will shrink tumors or help patients feel better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm non-small cell lung carcinoma uterine cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS COLORECTAL CANCER (CRC) KRAS G12C MUTATIONS KRAS G12S MUTATIONS NON-SMALL CELL LUNG CANCER UTERINE CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.